Lidocaine Crystalline powder (CAS 137-58-6) is a benchmark amide local anesthetic widely used in pharma research, dermo-aesthetics, dentistry, and topical R&D projects. Offered in crystalline/mesh/fluffy forms, it serves as a precise raw material for solubility screening, prototype formulations, and quality control. This guide combines chemical data (PubChem, NIST WebBook), industry use-cases and market outlook (IMARC, Verified Market Reports) so your lab can move faster with better decisions. Our safe worldwide delivery covers UK, USA, Germany, Sweden, Cyprus among others.
Properties & Forms
Identity and structure
- Substance: Lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide)
- CAS: 137-58-6 (base form). Its hydrochloride salt has different CAS entries (e.g., 6108-05-0 monohydrate; see ChemSpider).
- Formula: C₁₄H₂₂N₂O; molar mass ≈ 234.34 g/mol (NIST WebBook).
Physical chemistry (base form)
- Appearance: white crystalline powder, also sold as mesh fractions and fluffy for ergonomic blending.
- Melting point: ~76–79 °C (NIST WebBook).
- Solubility: good in organic solvents; hydrochloride salt is more water-soluble and often used in aqueous prototypes ( ECHA guidance).
Commercial forms for R&D
- Crystalline: stable QC reference, reliable calibration.
- Mesh (e.g., 60–100 mesh): higher surface area → faster dissolution, smoother premixes.
- Fluffy: lighter dosing, avoids clumping in creams or gels.
Applications in Industries (R&D angles)
- Cosmetics & dermo: prototypes of cooling creams and gels after procedures (research only, cosmetic compliance applies to marketable products).
- Tattoo & PMU: pre/post-tattoo gels with menthol or eucalyptus oil for sensorial freshness.
- Wellness / sex industry: delay gel concepts under strict jurisdictional compliance.
- Dental/medical R&D: Lidocaine hydrochloride for aqueous prototypes; requires stability and regulatory documentation.
Market Outlook & Trends
- The local anesthesia drugs market was estimated at ~USD 3.1–4.4B in 2024, projected to ~USD 4.3–6.5B by 2029–2034 (CAGR ~3.4–4.1%) (IMARC).
- Reports dedicated to lidocaine itself show ~USD 1.7–4.5B in 2024, reaching ~USD 3.5–6.2B by 2030–2033 (CAGR ~4.5–8.5%) ( Verified Market Reports).
Drivers (UK, USA, DE, SE, CY): outpatient procedures, dermo-aesthetic growth, tattoo/PMU demand, and stricter QC & traceability standards.
Procurement note: pair the base crystalline/mesh/fluffy with the HCl salt for aqueous projects; always lock SDS, COA, and mesh grade in R&D records.
Experiments & Lab Tips
Experiment – dissolution profile vs mesh
- Aim: compare crystalline vs 80-mesh lidocaine base in 96% ethanol.
- Method: 250 mg × 3 samples in 50 mL ethanol at 25 °C, 400 rpm stirring, measure clarity time.
- Expected: mesh reaches clarity faster due to larger surface area.
Lab tips:
- Store dry, sealed; use anti-static spoons for fluffy form.
- Run pilot batches (25–100 g) before scaling up.
- Record batch, SDS, COA, and mesh grade in every lab note.
Inspirations for R&D
- Tattoo numbing gels with menthol + eucalyptus oil.
- Anal/depilatory gels: test viscosity & migration.
- Dental pastes: sensory prototypes.
- QC workflows: DSC melting profile, ethanol vs IPA solubility curves.
Business Opportunities
Raw material testing saves costs and time. With lidocaine base you can validate compatibility, pH stability, and sensorial effects before expensive regulatory filings. Use market intelligence ( IMARC, Verified Market Reports) to benchmark demand and position pilot runs effectively.
Conclusion & CTA
Lidocaine crystalline powder (CAS 137-58-6) in crystalline/mesh/fluffy forms is a versatile R&D raw material across cosmetics, tattoo, wellness, and dental research. With safe worldwide delivery to UK, USA, Germany, Sweden, Cyprus, CristalChem ensures compliance and reliability.
Lidocaine Powder – safe worldwide delivery
Chemical Research Writer at CristalChem Academy. Passionate about chemistry, R&D, and turning laboratory insights into global wellness and industrial innovations.
